Economic analyses in clinical trials for cooperative groups: Operational considerations

Charles L. Bennett, Teresa M. Waters

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Clinical trials have served as valuable tools for evaluating new therapeutic strategies in the treatment of cancer. Traditionally, new pharmaceuticals and procedures have been appraised on the basis of effectiveness, efficacy, and safety. Recently, economic concerns have become increasingly important when considering treatment strategies for cancer patients. The national emphasis on assessing the costs of health care has focused primarily on the cost-effectiveness of resource allocation. Policy makers are exhibiting greater interest in economic data to supplement clinical data of new procedures and pharmaceutical agents before the approval and widespread application of such methodologies. Clinical trials have increasingly become viewed as a proper setting for such economic analyses. In this paper; we review operational details for carrying out economic analyses of clinical trials being conducted in the cancer cooperative group setting.

Original languageEnglish
Pages (from-to)448-453
Number of pages6
JournalCancer Investigation
Issue number5
StatePublished - 1997

Bibliographical note

Funding Information:
Dr. Bennett is a recipient of a Senior Carea Development Award from the Department of Veterans Affairs. We would like to thank survey respondents from each of the cooperative cancer clinical trial groups for their helpful comments.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Economic analyses in clinical trials for cooperative groups: Operational considerations'. Together they form a unique fingerprint.

Cite this